2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1800

A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome
Abstract Number: 1801

Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis
Abstract Number: 1802

Behcet’s Disease in the Southwestern United States
Abstract Number: 1803

Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study
Abstract Number: 1804

Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease
Abstract Number: 1805

Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease
Abstract Number: 1806

Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
Abstract Number: 1807

Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
Abstract Number: 1808

Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis
Abstract Number: 1809

Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
Abstract Number: 1810

Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts
Abstract Number: 1811

Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
Abstract Number: 1812

Characterization and Prevalence of Morbus Behçet in Switzerland
Abstract Number: 1813

Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Abstract Number: 1814

Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].